Sugi Predict

Sugi Predict / Compounds / SCHEMBL196180

SCHEMBL196180

SCHEMBL196180

C[Si](C)(OS(=O)(=O)C(F)(F)F)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 2/20 0.37
▸ NR1H3 Q13133 2/20 0.37
▸ ESR1 P03372 1/20 0.35
▸ ESR2 Q92731 1/20 0.35
▸ NR1I2 O75469 4/20 0.35
▸ RORA P35398 1/20 0.35
▸ RORC P51449 1/20 0.35
▸ RORB Q92753 1/20 0.35
▸ NR1H4 Q96RI1 1/20 0.35
▸ CA2 P00918 2/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA5A P35218 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ GPR3 P46089 2/20 0.34
▸ ACHE P22303 1/20 0.32
▸ CHRM1 P11229 2/20 0.32
▸ DRD2 P14416 2/20 0.32
▸ DRD4 P21917 2/20 0.32
▸ DRD3 P35462 2/20 0.32
▸ HSD17B10 Q99714 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL196247 0.85 NR1H2 (0.37) NR1H2NR1H3ESR1ESR2NR1I2
SCHEMBL2057888 0.82 KEAP1 (0.35) ESR1ESR2NR1I2CA2CA1
SCHEMBL537935 0.80 CA2 (0.36) NR1H2NR1H3NR1I2RORARORC
SCHEMBL28383560 0.79 HSD17B10 (0.36) ESR1ESR2NR1I2CA2CA1
SCHEMBL537975 0.78 CA2 (0.33) NR1H2NR1H3NR1I2RORARORC
SCHEMBL30998871 0.77 PSIP1 (0.34) NR1H2NR1H3NR1I2RORARORC
SCHEMBL2058140 0.74 PSIP1 (0.39) ESR1ESR2NR1I2CA2CA1
SCHEMBL2057567 0.74 ALDH1A1 (0.41) NR1I2CA2CA1CA5ACA9
SCHEMBL22735181 0.72 MAPT (0.32) ESR1ESR2HSD17B10ALDH1A1TDP1
SCHEMBL28769788 0.72 ALDH1A1 (0.35) NR1H2NR1H3NR1I2CA9DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102216202-A Sulfonate modified nanocrystals LIFE TECHNOLOGIES CORP 2011-10-12 — — CN claimed
US-20110220844-A1 SULFONATE MODIFIED NANOCRYSTALS Life Technologies Corporation 2011-09-15 — — US claimed
EP-2342161-A2 SULFONATE MODIFIED NANOCRYSTALS Life Technologies Corporation (US) 2011-07-13 — — EP claimed
WO-2010040111-A2 SULFONATE MODIFIED NANOCRYSTALS Life Technologies Corporation (US) 2010-04-08 — — WO claimed
EP-4737444-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS Gilead Sciences, Inc. (US) 2026-05-06 — — EP disclosed
US-12410146-B2 Processes and intermediates for preparing MCL1 inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 — — US disclosed
US-20250179004-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS GILEAD SCIENCES, INC. 2025-06-05 — — US disclosed
WO-2025046071-A1 PROCESS FOR THE PRODUCTION OF ESTETROL INTERMEDIATES ESTETRA SRL (BE) 2025-03-06 — — WO disclosed
US-12202782-B2 Processes and intermediates for preparing MCL1 inhibitors GILEAD SCIENCES, INC. (US) 2025-01-21 — — US disclosed
EP-4484435-A2 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS Gilead Sciences, Inc. (US) 2025-01-01 — — EP disclosed
US-12163188-B2 Polymerase compositions and methods Life Technologies Corporation (US) 2024-12-10 — — US disclosed
EP-4065567-B1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS GILEAD SCIENCES INC (US) 2024-09-11 — — EP disclosed
EP-1334975-A1 Silylation of hydroxyl group-containing compounds SHIN-ETSU CHEMICAL CO., LTD. (JP) 2003-08-13 — — EP disclosed
US-20030139619-A1 Silylation of hydroxyl groups SHIN-ETSU CHEMICAL CO., LTD. (JP) 2003-07-24 — — US disclosed
EP-0594291-B1 Processes for the production of 13-ether derivatives of milbemycins, and intermediates therefor SANKYO CO (JP) 2002-12-18 — — EP disclosed
EP-1142857-A1 PROCESSES FOR PRODUCING ACRYLIC ACID DERIVATIVE NIPPON SODA CO., LTD. (JP) 2001-10-10 — — EP disclosed
US-5705702-A REACTING AN ARYL GRIGNARD REAGENT WITH THIONYL CHLORIDE, THEN WITH TRIORGANOSILYL SULFONATE OR TRIORGANOSILYLHALIDE SHIN-ETSU CHEMICAL CO., LTD. (JP) 1998-01-06 — — US disclosed
US-5625078-A Processes for the production of 13-ether derivatives of milbemycins and novel intermediates therefor SANKYO COMPANY, LIMITED (JP) 1997-04-29 — — US disclosed
US-5461168-A Processes for the production of 13-ether derivatives of milbemycins, and intermediates therefor SANKYO COMPANY, LIMITED (JP) 1995-10-24 — — US disclosed
EP-0594291-A1 Novel processes for the production of 13-ether derivatives of milbemycins, and novel intermediates therefor SANKYO COMPANY LIMITED (JP) 1994-04-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410146-B2 Processes and intermediates for preparing MCL1 inhibitors MCL1, BAK1, BCL3 NR1H2 4220/4885NR1H3 4254/4885ESR1 4558/4885
US-12202782-B2 Processes and intermediates for preparing MCL1 inhibitors MCL1, BCL3, XIAP NR1H2 3577/4885NR1H3 3624/4885ESR1 4273/4885
US-12163188-B2 Polymerase compositions and methods POLN, POLI, POLRMT NR1H2 4590/4885NR1H3 4382/4885ESR1 3418/4885
US-20250179004-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS MCL1, BCL3, XIAP NR1H2 3577/4885NR1H3 3624/4885ESR1 4273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.